Shares of 4D Pharma PLC (LON: DDDD) today surged 9.67% after the company announced the appointment of an independent non-executive director Katrin Rupalla, PhD, which many analysts cheered as a strategic move.
Dr Rupalla has over 20 years experience in the pharmaceuticals industry having worked in both clinical and regulatory roles within the neuroscience and oncology specialities.
Her prior experience includes senior roles at Merck & Co., Celgene, Roche and Bristol-Myers Squibb (BMS).
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Dr Rupalla has led regional and global teams tasked with getting regulatory approvals for multiple new therapies including Opdivo, Rituxan, Yervoy, Xeloda, Revlimid, Avastin, and Vidaza, among others.
She will play a critical role in 4D pharma’s immediate and long-term clinical strategy across its Live Biotherapeutic development pipeline, including the application of the Rx platform and other pre-clinical projects.
Duncan Peyton, 4D’s CEO, commented: “We are delighted to be able to attract someone of Katrin’s calibre to our Board of Directors. Her vast experience guiding novel therapies through the clinic will be invaluable as we progress our pipeline of novel Live Biotherapeutics into and through the clinic. With her background so well aligned with 4D’s core focus areas of oncology and CNS, Katrin’s experience and network across Europe, the US and China will support 4D’s growth as we continue to expand our global profile.”
4D Pharma share price

4D Pharma shares today rallied 9.67% to trade at 170p having ended Tuesday’s session trading at 155p.
People who read this also read: